Dan Becker represents biotech and pharmaceutical companies in all areas of patent counseling, including life cycle management, patent portfolio development and restructuring, post-issuance proceedings, investment and transactional intellectual property due diligence, and offensive and defensive patent strategy. He is a registered patent lawyer.
Dan has extensive experience in pharmaceutical life cycle management, both for marketed pharmaceutical products and for products in late-stage clinical development that require additional patent term. Prior to joining Fenwick & West, Dan was responsible for worldwide prosecution of a second-generation patent family protecting the world's best-selling prescription pharmaceutical, including coordinating successful defense against 15 European opponents. For a venture-backed company repurposing a drug product that had earlier failed phase 3 clinical trials in a different indication, Dan designed a strategy for newly claiming the drug substance per se, including advice on new in vitro experiments, drafting, filing and prosecution of a new patent family, achieving allowance of Orange Book-listable claims shortly after acquisition of the company for $325M upfront plus $120M in contingent value rights. More recently, for another venture-backed company, Dan designed a patent strategy that led to new drug substance and drug product claims for a complex mixture API in phase 1 clinical trials; the company was acquired for $200M upfront, and the acquirer was then itself purchased for $1.2B. In 2012, in an effort to secure additional patent term for a newly-issued patent covering a French client's lead compound, Dan argued cross-motions for summary judgment in the District Court for the Eastern District of Virginia, advancing a patent term adjustment theory crafted in collaboration with a former colleague.
In his post-issuance practice, Dan has represented clients before the U.S. Patent and Trademark Office's Patent Trial and Appeal Board as lead counsel in inter partes reviews, interference proceedings, ex parte and inter partes reexamination proceedings, and appeal from ex parte reexamination and inter partes reexamination.
Before joining the firm, Dan was a partner in the IP and life sciences practices of a large general practice firm.
Dan has been recognized as an IP Star by Managing Intellectual Property (2019), a Life Science Star by LMG (2011-2018), a Leading Lawyer in Life Sciences by Chambers USA (2010-2016) and was recommended by The Legal 500 (US) in 2015, 2016 and 2018 in the categories of Venture Capital & Emerging Companies and Patent Portfolio Management and Licensing.
Prior to his legal career, Dan conducted research in molecular immunology and in eukaryotic gene expression. Certain of his publications are still being cited in the scientific literature.